Abstract
Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) remains an unvalidated antiviral target. A major challenge of specifically targeting HIV RNase H arises from the general lack of selectivity over RT polymerase (pol) and integrase (IN) strand transfer (ST) inhibitions. We report herein the synthesis and biochemical evaluations of three novel 3-hydroxypyrimidine-2,4-dione (HPD) subtypes carefully designed to achieve selective RNase H inhibition. Biochemical studies showed the two subtypes with an N-1 methyl group (9 and 10) inhibited RNase H in low micromolar range without siginificantly inhibiting RT polymerase, whereas the N-1 unsubstituted subtype 11 inhibited RNase H in submicromolar range and RT polymerase in low micromolar range. Subtype 11 also exhibited substantially reduced inhibition in the HIV-1 INST assay and no significant cytotoxicity in the cell viability assay, suggesting that it may be amenable to further structure-activity relationship (SAR) for identifying RNase H inhibitors with antiviral activity.
Original language | English (US) |
---|---|
Pages (from-to) | 2648-2659 |
Number of pages | 12 |
Journal | Journal of medicinal chemistry |
Volume | 59 |
Issue number | 6 |
DOIs | |
State | Published - Mar 24 2016 |
Bibliographical note
Funding Information:ACKNOWLEDGMENTS: This research was supported by the National Institutes of Health (AI100890 to S.G.S., M.A.P. and Z.W.) and partially by the Center for Drug Design, University of Minnesota.
Publisher Copyright:
© 2016 American Chemical Society.